RBC Europe’s Corbus Pharmaceuticals CRBP Stock Holding History

RBC Europe’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-107	Closed	-$22.2K	–	1073
2019 Q1	$22.2K	Sell	107 -41	-28%	-$9.04K	﹤0.01%	631
2018 Q4	$26K	Hold	148	–	–	﹤0.01%	581
2018 Q3	$33.6K	Hold	148	–	–	﹤0.01%	565
2018 Q2	$22.5K	Buy	+148	New	+$26.9K	﹤0.01%	652

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RBC Europe's CRBP Position: Q2 2019 in Review

RBC Europe sold out of Corbus Pharmaceuticals (CRBP) in Q2 2019, closing a stake of 107 shares — an estimated $22.2K sold.

RBC Europe first reported a position in CRBP in Q2 2018 and held it in 4 quarters. The position peaked at $33.6K in Q3 2018. 103 funds tracked by Wall St. Rank hold CRBP as of Q2 2019.

RBC Europe reported no remaining Corbus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
RBC Europe sold 107 Corbus Pharmaceuticals shares in Q2 2019, an estimated $22.2K.
RBC Europe first reported a position in Corbus Pharmaceuticals in Q2 2018 and held it in 4 quarters.
RBC Europe's Corbus Pharmaceuticals position peaked at $33.6K in Q3 2018.
103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2019.

Based on RBC Europe's 13F filing for Q2 2019, filed 9 Nov 2023.